Investing.com - Oppenheimer reiterated an Outperform stock rating and $30.00 price target on Immuneering Corporation (NASDAQ:IMRX) following the company’s presentation of pancreatic cancer drug data. The stock currently trades at $4.68 with a market cap of $304 million, and InvestingPro data indicates the company is undervalued relative to its Fair Value estimate.
The company reported 17.3-month median overall survival data for atebimetinib combined with mGnP in a Phase 2a study of 55 pancreatic ductal adenocarcinoma patients. The data was presented as an update at ASCO 2026.
Oppenheimer noted the survival signal compares favorably against historical benchmarks for first-line pancreatic cancer treatment. The firm conducted a survey of 34 physicians who viewed both the overall survival signal and tolerability profile as promising or very promising. According to InvestingPro Tips, the stock has delivered a high return over the last year with a 237% gain, though the company remains unprofitable.
The update followed a plenary presentation at ASCO 2026 by Revolution Medicines showing daraxonrasib doubled median overall survival versus chemotherapy in previously treated metastatic pancreatic cancer patients in the RASolute-302 study.
Oppenheimer said the ASCO update should raise awareness of atebimetinib and accelerate Phase 3 execution as the study is now recruiting patients. For deeper insights into IMRX’s financial health and growth prospects, investors can access the comprehensive Pro Research Report, available exclusively on InvestingPro for this and 1,400+ other US equities.
In other recent news, Immuneering Corporation has announced significant developments in its ongoing clinical trials. The company reported a median overall survival of 17.3 months in its Phase 2a trial for first-line metastatic pancreatic cancer patients treated with atebimetinib combined with modified gemcitabine/nab-paclitaxel. This data, which includes 55 patients, was presented at the American Society of Clinical Oncology Annual Meeting. The trial results showed a notable improvement compared to the 8.5 months median overall survival reported in a previous pivotal Phase 3 study of standard care treatments. Additionally, the company noted that treatment-related adverse events at Grade 3 or higher were primarily due to chemotherapy, with anemia and neutropenia being the most common. Immuneering also shared genetic data on atebimetinib resistance, revealing that acquired mutations in the MAPK pathway were rarely observed. This information was presented at the American Association for Cancer Research Annual Meeting. These recent developments highlight Immuneering’s progress in advancing its treatment options for pancreatic cancer.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
The fastest way to find out is with our Fair Value calculator. We use a mix of 17 proven industry valuation models for maximum accuracy. Get the bottom line for IMRX plus thousands of other stocks and find your next hidden gem with massive upside.